FRANKFURT (Reuters) -European companies playing key supporting roles in COVID-19 vaccine manufacturing are working to move production and supply chains closer to their customers to guard against trade restrictions that have interrupted supplies during the pandemic. Germany's Merck KGaA, whose Life Science unit is one of the world's largest makers of bioreactor gear and supplies, told Reuters it is pushing to spread its production network geographically so that fewer shipments have to cross customs borders. U.S. regulations in particular, which give priority to companies fulfilling U.S. government contracts, have posed a challenge for Merck as its seeks to meet soaring demand for supplies such as sterile fermentation bags and filters.
As if the euro football championships weren't providing enough nail-biting action, global markets have decided to jump on to the act in the closing hours of the first half of 2021. Major U.S. stock indices hit yet another record high overnight, but Asian stock markets, in a rare move, are looking the other way. And so the mood is distinctly cautious in early European trading with U.S. and European stock futures in the red, while the safe-haven U.S. dollar stands tall against its rivals.
Will the timely new product position Merck KGaA as an upstream supplier for the entire mRNA medicine world and allow it to reap the benefits, or is it unlikely to reward shareholders? To start, let's quickly review the scientific concepts at hand so that it's clear why Merck KGaA's new product is worth knowing about. As you may know, lipid molecules don't dissolve in water.